- Conditions
- Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor
- Interventions
- BT8009, Pembrolizumab
- Drug
- Lead sponsor
- BicycleTx Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Ocala, Florida • Orlando, Florida + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 1,799
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neoplasms
- Interventions
- Regorafenib (Stivarga, BAY73-4506)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 2 more
- Conditions
- Advanced Solid Tumors
- Interventions
- OSI-930
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Boston, Massachusetts
- Conditions
- Kidney Cancer
- Interventions
- Perifosine
- Drug
- Lead sponsor
- AEterna Zentaris
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Morristown, New Jersey • Armonk, New York
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers
- Interventions
- Autogene cevumeran, Atezolizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Bevacizumab, Sunitinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 25
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 19 more
- Conditions
- Kidney Cancer
- Interventions
- becatecarin
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Pazopanib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 15
- States / cities
- Duarte, California • Santa Monica, California • Aurora, Colorado + 12 more
- Conditions
- Wilms Tumor and Other Childhood Kidney Tumors
- Interventions
- laboratory biomarker analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Monrovia, California
- Conditions
- Kidney Neoplasm, Renal Mass
- Interventions
- Computed Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography, Technetium Tc-99m Sestamibi
- Procedure · Other · Radiation
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Renal Cell Cancer, Kidney Cancer
- Interventions
- Sunitinib Malate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Adrenal Cortical Cancer, Brain Cancer, Breast Cancer, CNS Cancer, Colon Cancer, HEENT Cancer, Hodgkin's Disease, Kaposi's Sarcoma, Liver Cancer, Lung Cancer, Non-Hodgkin's Lymphoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Sarcoma, Squamous Cell Carcinoma, Thyroid Cancer
- Interventions
- Proton-decoupled 31P MRS at 1.5T, 1H Spectroscopy at 1.5T and 3T
- Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 582 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1997 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer, Kidney Cancer, Stomach Cancer, Colorectal Cancer, Pancreas Cancer, Liver Cancer, Skin Cancer
- Interventions
- Blood Sample Collection
- Other
- Lead sponsor
- Delfi Diagnostics Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 2,992 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 56
- States / cities
- Homewood, Alabama • Peoria, Arizona • Fayetteville, Arkansas + 49 more
- Conditions
- Recurrent Melanoma, Recurrent Pancreatic Cancer, Recurrent Renal Cell Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- siRNA-transfected peripheral blood mononuclear cells APN401, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Renal Tumor Histology, Cutaneous Leiomyoma, Kidney Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 1,350 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Renal Pelvis Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Bladder Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Carcinoma, Metastatic Urethral Urothelial Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v6, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Melanoma
- Interventions
- Ipilimumab, Nivolumab, Tocilizumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Renal Cell Cancer, Kidney Cancer
- Interventions
- Sunitinib, Temsirolimus
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Wilms Tumor, Sarcoma, Spindle Cell, Sarcoma Rhabdoid, Childhood Sarcoma of Soft Tissue
- Interventions
- Not listed
- Lead sponsor
- Florida International University
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 14 participants
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Metastatic Head-and-neck Squamous-cell Carcinoma, Unresectable Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
- Interventions
- Time restricted eating (TRE)
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Digestive System Neoplasms, Endocrine Gland Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Breast Diseases, Renal Neoplasm, Solid Tumors
- Interventions
- Entinostat, Pembrolizumab
- Drug
- Lead sponsor
- Syndax Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer, Sarcoma
- Interventions
- stereotactic radiosurgery
- Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 11
- States / cities
- Des Moines, Iowa • Kalamazoo, Michigan • Papillion, Nebraska + 5 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Recombinant Human Lactoferrin
- Drug
- Lead sponsor
- Agennix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Stanford, California • Chicago, Illinois + 2 more
- Conditions
- Metastatic Renal Cell Carcinoma, Kidney Cancer
- Interventions
- Bevacizumab and Sunitinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v8, Stage II Renal Cell Cancer AJCC v8
- Interventions
- Magnetic Resonance Imaging, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Procedure · Other · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas